Literature DB >> 20041405

Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma.

Yujuan Xiong1, Jian-Hong Fang, Jing-Ping Yun, Jine Yang, Ying Zhang, Wei-Hua Jia, Shi-Mei Zhuang.   

Abstract

UNLABELLED: Based on microarray data, we have previously shown a significant down-regulation of miR-29 in hepatocellular carcinoma (HCC) tissues. To date, the role of miR-29 deregulation in hepatocarcinogenesis and the signaling pathways by which miR-29 exerts its function and modulates the malignant phenotypes of HCC cells remain largely unknown. In this study, we confirmed that reduced expression of miR-29 was a frequent event in HCC tissues using both Northern blot and real-time quantitative reverse-transcription polymerase chain reaction. More interestingly, we found that miR-29 down-regulation was significantly associated with worse disease-free survival of HCC patients. Both gain- and loss-of-function studies revealed that miR-29 could sensitize HCC cells to apoptosis that was triggered by either serum starvation and hypoxia or chemotherapeutic drugs, which mimicked the tumor growth environment in vivo and the clinical treatment. Moreover, introduction of miR-29 dramatically repressed the ability of HCC cells to form tumor in nude mice. Subsequent investigation characterized two antiapoptotic molecules, Bcl-2 and Mcl-1, as direct targets of miR-29. Furthermore, silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29, whereas overexpression of these proteins attenuated the effect of miR-29. In addition, enhanced expression of miR-29 resulted in the loss of mitochondrial potential and the release of cytochrome c to cytoplasm, suggesting that miR-29 may promote apoptosis through a mitochondrial pathway that involves Mcl-1 and Bcl-2.
CONCLUSION: Our data highlight an important role of miR-29 in the regulation of apoptosis and in the molecular etiology of HCC, and implicate the potential application of miR-29 in prognosis prediction and in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20041405     DOI: 10.1002/hep.23380

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  264 in total

1.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia.

Authors:  Nicholas J Hand; Amber M Horner; Zankhana R Master; LaTasha A Boateng; Claire LeGuen; Marina Uvaydova; Joshua R Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

3.  MicroRNA-21 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting activator protein-1.

Authors:  Yumei Li; Limei Yan; Wenyu Zhang; Nan Hu; Wei Chen; Hui Wang; Min Kang; Hesheng Ou
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

4.  Epigenetic changes mediated by microRNA miR29 activate cyclooxygenase 2 and lambda-1 interferon production during viral infection.

Authors:  Jiali Fang; Qian Hao; Li Liu; Yongkui Li; Jianguo Wu; Xixiang Huo; Ying Zhu
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29.

Authors:  Hui Li; Emilia Solomon; Sara Duhachek Muggy; Danqiong Sun; Anna Zolkiewska
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 6.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 7.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

8.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

9.  MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma.

Authors:  Ru-Ting Xie; Xian-Ling Cong; Xiao-Ming Zhong; Ping Luo; Hui-Qiong Yang; Gai-Xia Lu; Pei Luo; Zheng-Yan Chang; Ran Sun; Ting-Miao Wu; Zhong-Wei Lv; Da Fu; Yu-Shui Ma
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

10.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.